ACT-453859 and Setipiprant in Healthy Subjects

Phase 1, randomised, double-blind trial of ACT-453859 in asthma and allergic rhinitis (AR), sponsored by Idorsia. Primary endpoints: Area under the plasma concentration-time curve from time zero to time t at 72 hours, Area under the plasma concentration-time curve from time zero to infinity at 72 hours and 2 more. Started Dec 2011; status: completed.